Clinical Trials Directory

Trials / Conditions / Complicated Urinary Tract Infection

Complicated Urinary Tract Infection

26 registered clinical trials studyying Complicated Urinary Tract Infection — 3 currently recruiting.

StatusTrialSponsorPhase
Active Not RecruitingClinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
NCT06824129
QIAGEN Gaithersburg, Inc—
RecruitingA Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With C
NCT06672978
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)Phase 2
RecruitingA Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
NCT05733104
Pfizer—
UnknownStudy of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (
NCT03630081
WockhardtPhase 3
CompletedP3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available T
NCT05905055
Meiji Seika Pharma Co., Ltd.Phase 3
UnknownA Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI
NCT05826990
AllecraPhase 2
CompletedEfficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects
NCT05887908
Meiji Seika Pharma Co., Ltd.Phase 3
CompletedStudy of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (
NCT04979806
WockhardtPhase 3
CompletedEvaluating UTI Outcomes in at Risk Populations
NCT05385536
Pathnostics—
RecruitingSingle Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children
NCT04876131
Murdoch Childrens Research InstitutePhase 4
UnknownMeropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
NCT05060419
Qilu Pharmaceutical Co., Ltd.Phase 2
UnknownBacterial Metallophores in the Diagnosis of Acute Pyelonephritis
NCT05674032
Thomayer University Hospital—
UnknownEfficacy of Intravenous Fosfomycin in the Treatment of Complicated Urinary in Real-life Conditions.
NCT04076436
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla—
CompletedStudy to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromid
NCT03788967
Spero TherapeuticsPhase 3
CompletedMK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-
NCT03230838
Merck Sharp & Dohme LLCPhase 2
CompletedEvaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults Wit
NCT03445195
Entasis TherapeuticsPhase 2
CompletedEfficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Int
NCT03293485
Merck Sharp & Dohme LLCPhase 3
CompletedStudy of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Comp
NCT02728089
Merck Sharp & Dohme LLCPhase 3
CompletedA Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI)
NCT02486627
Achaogen, Inc.Phase 3
CompletedOptimising Diagnosis and Antibiotic Prescribing for Acutely Ill Children in Primary Care
NCT02024282
KU LeuvenN/A
CompletedCeftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
NCT01644643
PfizerPhase 3
CompletedStudy Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Uri
NCT01345929
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 3
CompletedA Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUT
NCT01096849
Achaogen, Inc.Phase 2
CompletedSafety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
NCT00921024
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 2
CompletedComparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
NCT00690378
PfizerPhase 2
No Longer AvailableExpanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
NCT04682834
Iterum Therapeutics, International Limited—